N-(2-氨基乙基)环丙烷羧酰胺 | 53673-05-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-氨基乙基)环丙烷羧酰胺
• 中文别名: N-2-胺乙基环丙酰胺
• 英文名称: N-(2-aminoethyl)cyclopropanecarboxamide
• CAS: 53673-05-5
• 化学式: C₆H₁₂N₂O
• mdl: MFCD09927906
• 分子量: 128.174
• InChiKey: IOKJAZWKXFLGJN-UHFFFAOYSA-N

物化性质

• 沸点：
  326.6±21.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)环丙烷羧酰胺 、 苯基缩水甘油醚 生成 N-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethyl]cyclopropanecarboxamide
  参考文献：
  名称：

  CH605666

  摘要：

  公开号：
• 作为产物：
  描述：

  乙二胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 N-(2-氨基乙基)环丙烷羧酰胺
  参考文献：
  名称：

  CH605666

  摘要：

  公开号：

文献信息

• NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  公开号：EP3929185A1

  公开（公告）日：2021-12-29

  The present invention relates to a nitrogen-containing fused ring compound, a preparation method and use thereof. Specifically, the present invention relates to a compound having the structure of Formula (X), a stereoisomer, tautomer or mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph or solvate thereof, or a stable isotope derivative, metabolite or prodrug thereof. The compound of the invention may have the structure of Formula (I) or Formula (II). These compounds are useful for the treatment of an abnormal cell proliferation disease (e.g., cancer).         R-L-R3     (X)

  本发明涉及一种含氮融合环化合物，其制备方法和用途。具体而言，本发明涉及具有化学式（X）结构的化合物，其立体异构体、互变异构体或它们的混合物，药学上可接受的盐、共晶体、多型体或溶剂合物，或其稳定同位素衍生物、代谢物或前药。本发明的化合物可能具有化学式（I）或化学式（II）的结构。这些化合物对于治疗异常细胞增殖疾病（例如癌症）是有用的。 R-L-R3（X）
• PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
  申请人：RAQUALIA PHARMA INC.

  公开号：US20150291582A1

  公开（公告）日：2015-10-15

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑吡啶衍生物，其具有钠离子电压门控通道的阻滞活性，包括TTX-S通道，并且可用于治疗或预防涉及钠离子电压门控通道的疾病和疾病。本发明还涉及包括这些化合物的制药组合物以及在预防或治疗涉及钠离子电压门控通道的疾病中使用这些化合物和组合物的用途。
• Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
  作者：Yao-Hao Xu、Yu-Tao Hu、Shu-Min Xu、Bing-Bing Song、Hao Yuan、Dan-Dan Zhao、Shi-Yao Guo、Zhi Jiang、Li-Yuan Wei、Yong Rao、Jia-Heng Tan、Shi-Liang Huang、Qing-Jiang Li、Shuo-Bin Chen、Zhi-Shu Huang

  DOI：10.1021/acs.jmedchem.3c00085

  日期：2023.6.8

  synthesized a new series of bouchardatine derivatives to discover more potential modulators. We applied the dual-parametric high-content screening (HCS) to evaluate their AMP-activated protein kinase (AMPK) modulation and CRC proliferation inhibition effect simultaneously. And we found their antiproliferation activities were highly correlated to AMPK activation. Among them, 18a was identified with nanomole-level

  代谢重编程是肿瘤发生的重要标志。调节重新编程的能量代谢是一种有吸引力的抗癌治疗策略。我们之前发现了一种天然产物Bouchardatine可以调节有氧代谢并抑制结直肠癌细胞 (CRC) 的增殖。在此，我们设计并合成了一系列新的 Bouchardatine 衍生物，以发现更多潜在的调节剂。我们应用双参数高内涵筛选（HCS）同时评估其AMP激活蛋白激酶（AMPK）调节和CRC增殖抑制作用。我们发现它们的抗增殖活性与 AMPK 激活高度相关。其中，18a已被鉴定对多种 CRC 具有纳摩尔级的抗增殖活性。有趣的是，评估发现18a选择性上调氧化磷酸化（OXPHOS）并通过调节能量代谢抑制增殖。此外，该化合物有效抑制 RKO 异种移植物生长以及 AMPK 激活。总之，我们的研究确定18a是 CRC 治疗的有希望的候选者，并提出了一种通过 AMPK 激活和 OXPHOS 上调的新型抗 CRC 策略。
• .beta.-Adrenergic blocking agents. 23. 1-(Substituted-amido)phenoxy-3-[[(substituted-amido)alkyl]amino]propan-2-ols
  作者：M. S. Large、L. H. Smith

  DOI：10.1021/jm00357a008

  日期：1983.3

  The synthesis of a series of 1-phenoxy-3-[(amidoalkyl)amino]propan-2-ols, in which the phenoxy ring is variously substituted with ortho and para amidic moieties, is described. Several of the compounds have beta-blocking potency comparable to that of propranolol and cardioselectivity similar to that of practolol, when given intravenously to anesthetized cats. In contrast to previous findings with cardioselective beta blockers, both ortho and para substitution give variable degrees of cardioselectivity. Potency, however, is favored by ortho substitution.
• .beta.-Adrenergic blocking agents. 22. 1-Phenoxy-3-[[(substituted-amido)alkyl]amino]-2-propanols
  作者：M. S. Large、L. H. Smith

  DOI：10.1021/jm00353a004

  日期：1982.11

  The synthesis of a series of 1-phenoxy-3-[[(substituted-amido)alkyl]amino]-2-propanols is described. Many of the compounds are more potent than propanolol as beta blockers, while having cardioselectivity comparable to that of practolol, when given intravenously to anesthetized cats. The structure-activity relationships shown by this series of compounds provide further evidence that the addition of substituents to the alkylamino moeity of a beta blocker can confer cardioselectivity and that amidic substituents are remarkably effective.